SCHEMBL26696017

SCHEMBL26696017

COC(=O)c1c2cc(OCc3cnn(C)c3)ccc2nn1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
HSD17B10 Q99714 1/20 0.40
POLB P06746 1/20 0.39
CYP2C19 P33261 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
CYP3A4 P08684 1/20 0.38
KCNH2 Q12809 1/20 0.38
ATM Q13315 1/20 0.38
MET P08581 1/20 0.37
CYP11B1 P15538 1/20 0.36
RXFP1 Q9HBX9 1/20 0.36
PDGFRB P09619 1/20 0.35
FLT4 P35916 1/20 0.35
FLT3 P36888 1/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
HPGD P15428 1/20 0.35
MCHR1 Q99705 2/20 0.35
NMT1 P30419 2/20 0.35
NMT2 O60551 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26696045 0.89 NMT1 (0.38) MEN1KMT2AHSD17B10CYP11B1RXFP1
SCHEMBL30714579 0.83 CYP3A4 (0.42) MEN1KMT2ACYP3A4KCNH2SMN1; SMN2
SCHEMBL26696022 0.83 CYP3A4 (0.42) MEN1KMT2ACYP3A4KCNH2SMN1; SMN2
SCHEMBL26696010 0.81 HPGDS (0.41) KMT2ACYP3A4KCNH2SMN1; SMN2
SCHEMBL26874763 0.80 MEN1 (0.34) MEN1KMT2AHSD17B10NPSR1MET
SCHEMBL26696031 0.78 MCHR1 (0.37) MEN1KMT2AHSD17B10POLBCYP3A4
SCHEMBL3597145 0.78 PLA2G2A (0.48) MEN1KMT2AHSD17B10POLBNPSR1
SCHEMBL26696046 0.77 PDE4A (0.49) MEN1KMT2AHSD17B10CYP2C19CYP3A4
SCHEMBL26696061 0.77 PARP10 (0.47) MEN1KMT2ANPSR1KCNH2SMN1; SMN2
SCHEMBL26696011 0.76 NMT1 (0.48) MEN1KMT2ASMN1; SMN2NMT1NMT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS UNIV LEUVEN KATH (BE) 2025-12-11 US disclosed
CN-119968362-A Indazole derivatives for the treatment of TRPM3 mediated disorders 勒芬天主教大学 2025-05-09 CN disclosed
EP-4499624-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS Katholieke Universiteit Leuven KU Leuven Research & Development (BE) 2025-02-05 EP disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed
WO-2023230540-A2 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2023-11-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250376461-A1 INDAZOLE DERIVATIVES FOR TREATING TRPM3-MEDIATED DISORDERS TRPV3, TRPM2, TRPV1 MEN1 1744/4885KMT2A 3017/4885HSD17B10 3411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.